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Abstract 
Background:  Devices used to improve polyp detection during colonoscopy have seldom been 
compared with each other.  
Methods: We performed a 3-center prospective randomized trial comparing high-definition 
(HD) forward-viewing colonoscopy alone to HD with Endocuff to HD with EndoRings to the Full 
Spectrum Endoscopy (FUSE) system. Patients were age ≥50 years and had routine indications 
and intact colons. The study colonoscopists were all proven high-level detectors. The primary 
endpoint was adenomas per colonoscopy (APC) 
Results: Among 1,188 patients who completed the study, APC with Endocuff (APC Mean ± SD 
1.82 ± 2.58), EndoRings (1.55 ± 2.42), and standard HD colonoscopy (1.53 ± 2.33) were all 
higher than FUSE (1.30 ± 1.96,) (p<0.001 for APC). Endocuff was higher than standard HD 
colonoscopy for APC (p=0.014) . Mean cecal insertion times with FUSE (468 ± 311 seconds) and 
EndoRings (403 ± 263 seconds) were both longer than with Endocuff (354 ± 216 seconds) 
(p=0.006 and 0.018, respectively). 
Conclusions 
For high-level detectors at colonoscopy, forward-viewing HD instruments dominate the FUSE 
system, indicating that for these examiners image resolution trumps angle of view.  Further, 
Endocuff is a dominant strategy over EndoRings and no mucosal exposure device on a forward-
viewing HD colonoscope. 
Introduction 
Colonoscopy prevents colon cancer through detection and removal of precancerous lesions 
1
. 
More-effective detection of adenomas is associated with better prevention of postcolonoscopy 
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cancer 
2,3
.  Critical elements of effective detection include optimal maneuvering of the 
colonoscope to expose mucosal behind folds,  adequate distension,  clean colon, and sufficient 
inspection time to  visually process the exposed mucosa 
4
. The use of high-definition 
colonoscopes adds to detection 
5
 and is now widely considered fundamental to detection and 
effective therapeutics. 
 
Although optimal maneuvers and lesion recognition ability during colonoscopy examination are 
the core of effective detection and can be taught to colonoscopists 
6,7
, adjunctive devices and 
techniques have also been widely investigated. These include tools to highlight flat and subtle 
precancerous lesions such as chromoendoscopy 
8,9
 and electronic chromoendoscopy 
10,11
, as 
well as mucosal exposure devices such as Endocuff 
12
, EndoRings 
13
, and ultra-wide angle 
endoscopes such as Full Spectrum Endoscopy (FUSE)
14
. 
 
Available data with mucosal exposure devices have often compared such devices with standard 
colonoscopy in 2-arm studies.  The most robust data is available for Endocuff 
12,15-18
, and 
indicates that Endocuff produces an average 7% gain in the adenoma detection rate (ADR) 
12
.  
Data are more limited with EndoRings, and are largely from a single randomized tandem study 
showing that EndoRings reduced the miss rate for adenomas 
14
.  Data on the value of the FUSE 
system have been mixed, with FUSE resulting in less missing in an initial tandem study 14, but no 
improvement in a subsequent randomized trial in patients with positive fecal immunochemical 
tests 19.  To the extent that mucosal exposure devices are effective, it remains uncertain which 
colonoscopists can improve detection with these devices. That is, do all endoscopists improve 
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detection by use of mucosal exposure devices, or are the benefits confined or result 
predominantly for colonoscopists with low baseline ADRs?  
 
In this study, we sought to evaluate the utility of mucosal exposure devices in the hands of 
colonoscopists with known high ADRs when using standard equipment.  In addition, we sought 
to directly compare 3 mucosal exposure devices with each other, namely Endocuff versus 
EndoRings versus FUSE. 
 
Methods 
 
We conducted  a prospective randomized controlled trial comparing high-definition (HD) 
forward-viewing white-light colonoscopy (referred to as the standard or control arm), versus 
HD forward-viewing white-light colonoscopy plus Endocuff, versus HD forward-viewing white-
light colonoscopy with EndoRings versus the Full Spectrum Endoscopy (FUSE) system.  Patients 
were randomized in a 1:1:1:1 ratio.  The study was conducted at 3 academic endoscopy units in 
Indianapolis, Indiana; Milan, Italy; and New York, New York. The study was reviewed and 
approved by the Institutional Review Boards at Indiana University on January 14, 2015, and all 
subjects gave informed consent.  The trial was registered at Clinicaltrials.gov (NCT02345889).   
 
Participants were ≥50 years and undergoing colonoscopy for colorectal cancer screening, 
surveillance of polyps, or symptoms. Patients were excluded if there was any previous surgical 
resection of the colon, if there was a known colonic stricture or severe diverticular disease that 
might impede passage of the colonoscope with Endocuff or EndoRings, if there was a known 
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coagulopathy, for inability to provide informed consent, for any known polyp syndrome or 
inflammatory bowel disease, or Lynch syndrome, or if the indication was a known therapeutic 
procedure including polypectomy (Table 1).  Patients were excluded after randomization if their 
bowel preparation was considered inadequate for polyp examination, if the patient was found 
to have a polyp syndrome (World Health Organization criteria were used to classify patients 
with serrated polyposis syndrome 
20
) based on the findings of the colonoscopy, or if the patient 
was diagnosed with inflammatory bowel disease during the study colonoscopy. As part of this 
intent to treat analysis, patients remained in the analysis if Endocuff or EndoRings on a 
pediatric colonoscope could not pass the sigmoid colon. 
 
 
Interventions 
 
The study was performed at 3 sites, 2 in the United States and 1 in Italy.  The original plan was 
to conduct the study at 4 sites, but the fourth site never initiated the trial.  At each site one 
endoscopist with a proven high (≥40% in screening colonoscopy) baseline ADR (DR, AR, and SG) 
performed every withdrawal.  All 3 sites had extensive experience with control arm equipment, 
FUSE, and Endocuff before initiation.  Two sites were less familiar with EndoRings and the 
endoscopists performed enough procedures with EndoRings before study initiation to be very 
familiar with its use.  Fellows were allowed to insert the colonoscope, but cecal insertion times 
were evaluated separately when fellows participated in insertion. 
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A computer-generated sequence was used to randomize the patients.  Each site was provided 
with a series of opaque envelopes numbered sequentially with the concealed randomization.  
Enrollment and assignment of patients to study arms occurred at the individual sites. The 
randomization was revealed only after the patient provided informed consent.   
 
At all 3 sites, Olympus HD colonoscopes were used for the control arm and the arms with 
Endocuff and EndoRings.  These were 190 series or H180 series colonoscopes, and the 
colonoscopists had the discretion to select an adult or pediatric instrument.  If an adult 
instrument could not pass an angulated sigmoid, the protocol required an attempt with a 
pediatric instrument in the same randomization arm.  Thus, patients randomized to Endocuff 
were required to have an attempt using the pediatric colonoscope with the pediatric Endocuff 
device. 
 
The resolution of the FUSE system was improved by the manufacturer while the study was in 
progress.  All 3 sites had access and incorporated the most up to date FUSE colonoscopes as 
they became available.  Both adult and pediatric FUSE colonoscopes were available at each site. 
 
The Endocuff device used was the original device with 2 rows of fingers (Arc Medical Design, 
Leeds, England). The EndoRings device was manufactured in Israel by EndoAid Ltd (Caesarea, 
Israel).  During the study, the device was modified from a 3 ring device to a 2 ring device, and 
the EndoRings used were changed as soon as the new device was available.  
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The FUSE system and colonoscopes were provided by Endochoice (Marrietta, Ga).  The 
EndoRings devices were provided by EndoAid.  The Endocuff devices were provided by the U.S. 
Endocuff distributor (Medivators Inc, Minneapolis, Minn).  No other industry support was 
provided for the trial. There was no industry involvement in the design of the trial or its 
conduct, and no industry had access to or reviewed the study data or the manuscript before 
publication. 
 
Each of the study endoscopists was asked to force the inspection time during withdrawal to 
approximately 8 minutes, in order to remove inspection time as a variable that could affect the 
detection results. Inspection time was measured during withdrawal by an assistant using a 
stopwatch. The stopwatch was started as soon as the cecum was cleaned and cecal inspection 
initiated. It was stopped for all maneuvers, including polypectomy and biopsy, and during all 
washing and suctioning of the colon.   For the FUSE device, the endoscopist tried to observe all 
3 screens, but 2 individuals (usually the technician and the registered nurse in the room) were 
assigned to watch the 2 lateral images (one assistant assigned to each screen) to help ensure 
that any exposed polyp was recognized. 
 
 
Outcomes 
The primary outcome was the rate of conventional adenomas per colonoscopy (APC).  
Secondary outcomes included the adenoma detection rate (ADR; percent of patients with ≥1 
conventional adenoma), sessile serrated polyps per colonoscopy (SSPC; number of sessile 
serrated polyps per colonoscopy), the sessile serrated detection rate (SPDR or number of 
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patients with ≥ 1 sessile serrated polyp), the colonoscope insertion times, the failure rate of 
insertion, and the detection targets noted above for the right side of the colon (cecum, 
ascending, and hepatic flexure).  No interim analysis was performed. 
 
Conventional adenomas were uniformly dysplastic lesions that were characterized as tubular, 
tubillovillous or villous with dysplasia as low grade or high grade.  Serrated class lesions 
included hyperplastic polyps, sessile serrated polyps, and traditional serrated adenomas. 
 
Because of failure of initiating the study at 1 planned site, and slow randomization at another, 
randomization was continued beyond the initial planned number at 2 sites (see results).  
Proximal colon refers to the cecum, ascending colon, and hepatic flexure. 
 
Sample size and statistical analysis 
 
Based on previous studies at Indiana University we estimated that the baseline APC in the 
standard colonoscopy group would be 1.7 with a coefficient of variation of 1.5.  In order to 
demonstrate an increase in APC to 2.2 ( an absolute increase of 0.5 or a 29% increase), in any of 
the 3 increased mucosal exposure groups, a sample size of 287 patients per group, or total 
sample of 1,148 subjects was needed, assuming 80% power, and 2-sided 5% significance level. 
 
Generalized estimating equation (GEE) methods were used to analyze the combined data 
across all 3 sites, using site as the cluster effect.  Age and Boston Bowel Preparation Score 
(BBPS) assumed normal distributions, insertion and withdrawal times assumed log-normal 
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distributions, count data used a negative binomial model, and binary data used logistic 
regression.  Similar analyses, without using GEE for clustering, were performed for analyses of 
each site separately.  Pair-wise tests between all groups were performed when the overall 
group effect was significant. A 5% significance level was used for all tests, with no adjustment 
for multiple comparisons.  Analyses were performed using SAS version 9.4 (SAS institute, Inc, 
Cary, NC).  
To assess the effect of changing the FUSE and EndoRings technology during the study, APC was plotted 
against time for the EndoRings and FUSE groups, with a spline added to the plot to evaluate trends. 
 
Results 
 
Data on patients screened, deemed ineligible, and refusal to participate were collected only in 
Indianapolis.  The flow of patients through the study, including those excluded after 
randomization at all 3 sties, are described in Figure 1.  
Exclusions after screening and before randomization were tracked at Indianapolis only.  
Subjects who passed initial screening at Indianapolis but were excluded before randomization 
included 17 identified to have some degree of prior colon resection, 4 were referred for a 
previous incomplete colonoscopy (this reason for referral was not evident to screeners in the 
initial portion of the study), 9 had evidence of inflammatory bowel disease, 4 had serrated 
polyposis syndrome, 1 had familial adenomatous polyposis, 1 had a positive fecal  blood test, 
and 6 were considered unable to give informed consent by the investigator for reasons 
including dementia, anxiety, and inadequate English language skill.   Seventeen were excluded 
by the investigator based on evidence of severe sigmoid diverticular disease in prior 
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colonoscopy reports (considered to make passage of the colonoscope with Endocuff or 
EndorRings likely to fail) or recent diverticulitis. 
 
There were 1262 patients randomized, of whom 74 were excluded after randomization (Figure 
1).   One patient was excluded from the control arm for failure to intubate the cecum (Figure 1).  
Three patients were excluded when they were recognized to have to have serrated polyposis 
syndrome during the study colonoscopy. There were 6 patients randomized to EndoRings and 4 
to Endocuff in whom the instrument could not pass the sigmoid with either adult or pediatric 
versions who were included in the intent to treat analysis. There were 3 patients in the 
EndoRings arm and 1 in the Endocuff arm in whom the adult scope with device could not pass 
the sigmoid but the pediatric colonoscope and device were successfully passed to the cecum. In 
one patient the FUSE processor failed during the procedure and could not be promptly 
repaired. The procedure was completed using a standard Olympus colonoscope and the patient 
was included in the study. 
 
There were 1,188 subjects who completed the study, of whom 299 were randomized to 
Endocuff, 295 (Figure 2) to EndoRings, 299 to FUSE, and 295 to the control arm colonoscopy. 
The mean age of all subjects who completed the study was 62.6 (8.3) years and there were 582 
(49%) women.  There were 784 subjects who completed the study at Indianapolis, 302 at Milan, 
and 102 at New York.  Table 2 shows demographic features and procedure indications for the 4 
colonoscopy groups.  There were no significant differences in these factors between groups, 
either overall or at the individual study sites.  More than 90% of patients had polyp surveillance 
or screening as their indication. 
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Detection 
Considering only patients with the indication screening and who were randomized to the 
control arm, the fraction of subjects with at least one conventional adenoma (the adenoma 
detection rate or ADR using standard forward-viewing high-definition instruments) was 39 of 64 
subjects (61%) at Indianapolis, 19 of 44 (43%) at Milan, and 16 of 19 (84%) at New York, 
consistent with previous internal data at each site that the study endoscopists were high-level 
detectors.  
 
Table 3 summarizes detection in each study arm for all sites combined and individual sites.  The 
control colonoscopy arm, Endocuff, and EndoRings were all superior to FUSE for the primary 
endpoint (p < 0.001).  Overall, the highest APC was achieved with Endocuff at 1.82 (2.58).  
Endocuff was superior to control colonoscopy (0.014).  The most marked differences in 
detection with Endocuff were in New York, where APC was 2.00 (2.34) with Endocuff and <1 
with the other 3 modalities (0.75 ± 0.94 for EndoRings, 0.80 ± 1.37 for FUSE, 0.92 ± 1.15 for 
control).  There were no differences in Indianapolis (p=0.151) or Milan (p=0.848) between the 
modalities for the primary endpoint. 
 
The adenoma detection rate (ADR) was also significantly higher with Endocuff, EndoRings, and 
control colonoscopy compared to FUSE (p≤0.006).  Further, Endocuff was superior to EndoRings 
(p < 0.001) and control colonoscopy (p=0.003).  There were no significant differences between 
study arms in ADR within sites.  Similar findings were observed for the polyp detection rate 
(PDR) as were seen with ADR. 
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Evaluation by location in the colon showed that APC was higher in the right side of the colon 
(cecum, ascending, and hepatic flexure) for Endocuff (p<0.001), EndoRings (p=0.043) and 
control (p=0.003) compared twithFUSE (Supplementary Table 1).  APC for Endocuff in the right 
side of the colon was higher than control colonoscopy (p=0.034).  When analyzed by site, APC 
with Endocuff was higher in the right side of the colon in New York when compared with 
EndoRings (p=0.005) and control (p=0.030), but there were no differences in right-sided colon 
ADR between modalities in Indianapolis (p=0.563) or in Milan (p=0.966).  Very similar 
differences between modalities were seen in right-sided colon ADR at New York specifically; 
however, these differences in right-sided colon ADR between modalities were again not seen in 
Indianapolis (p=0.382) or Milan (p=0.805). 
The detection endpoints in a per protocol analysis are shown in Supplementary Table 2.  
Compared with the ITT analysis shown in Table 3, the per protocol analysis does not include the 
10 patients in whom the colonoscope could not be passed through the sigmoid with a device on 
the tip and the one patient in whom the FUSE system failed.  Differences in results between the 
ITT and PP analyses were minor. 
 
There were no differences between modalities in APC for conventional adenomas ≥10 mm 
either overall (p=0.306) or at any of the study sites.  Supplementary Table 1 shows the actual 
numbers of histologically identified conventional adenomas and sessile serrated polyps 
according to lesion size and location in the colon (right side of colon including cecum, ascending  
flexure, and hepatic flexure vs distal to the hepatic flexure). 
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There were some statistically significant differences in detection of SSPs between modalities 
(Table 3), but the trends were not consistent and although statistically significant, were 
numerically minor.   
Because the technology for FUSE and Endorings were changed during the study, APC was 
plotted against time for each technology, and no significant trends over time were observed for 
FUSE (p=0.46) or EndoRings (p=0.83). 
 
Procedure Times 
 
For the entire study, cecal insertion time was longer with FUSE compared to Endocuff (p=0.006) 
and control colonoscopy (p=0.016) (Table 4).  Further, EndoRings insertion time was longer than 
Endocuff (p=0.020).  A gastroenterology fellow was involved in the insertion phase in 39% of 
colonoscopies at Indianapolis, 61% of colonoscopies in Milan, and none of the colonoscopies in 
New York.  When only colonoscopies in which no fellow participated in insertion were 
considered, the cecal insertion time was still longer with FUSE than the other 3 arms (p ≤ 0.017) 
and EndoRings was longer than Endocuff (p=0.014).  When insertion times by site were 
evaluated, FUSE was longer than Endocuff (p≤0.02) and standard (p≤0.03) at all sites, FUSE was 
longer than EndoRings in Indianapolis, and EndoRings was longer than Endocuff (p=0.023) and 
standard (p=0.003) in New York, and FUSE was longer than EndoRings (p=0.004) and standard 
was longer than Endocuff (p=0.050) in Milan.   
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The mean Boston Bowel Preparation Score overall was 8.12 (1.33), with no significant 
difference between the study arms, but was higher at Indianapolis (8.75 ± 0.84) and New York 
(8.47 ± 1.23) than at Milan (6.39 ± 0.76). 
There were no colorectal perforations in any of the study patients. 
Discussion 
 
In this prospective randomized controlled trial we compared adenoma detection with a control 
arm of HD forward-viewing colonoscopy with HD forward-viewing colonoscopy with the 
adjunctive mucosal exposure devices Endocuff and EndoRings, and with the Full Spectrum 
Endoscopy (FUSE) colonoscopy system.  Although a number of studies have compared 
individual mucosal exposure devices with standard colonoscopy, to our knowledge this is the 
first study to compare mucosal exposure devices with each other.  
 
A principal finding of our study was that the FUSE colonoscope system was inferior to high-
definition forward-viewing Olympus colonoscopes with or without adjunctive devices. Thus, 
adenomas per colonoscopy (APC) and the adenoma detection rate (ADR) were higher with 
Olympus colonoscopes compared with the FUSE system.  This result is different than that 
obtained in the initial tandem colonoscopy study comparing the FUSE system with standard 
definition colonoscopes 14, which found that FUSE was superior for detection. Further the result 
is different from a prospective randomized trial comparing an early generation of FUSE 
colonoscopes to standard-definition forward-viewing colonoscopes in a FIT positive population 
in Italy 
19
.  In that study, there was no difference in detection between the very wide angle FUSE 
system and the forward-viewing standard-definition colonoscopes.  However, there was a non-
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significant trend in that study toward better detection of large adenomas by standard 
endoscopy.  In our study, we used high-definition Olympus colonoscopes, and also used state-
of-the-art FUSE instruments as they became available during the study interval. Although the 
FUSE colonoscopes were also considered HD, our subjective impression is that the resolution of 
the Olympus instruments was superior to FUSE. Our results indicate that in the hands of high-
level detectors, high-image resolution is more important to detection than angle of view. Thus, 
skilled examiners appear to be able to compensate for a more limited angle of view by their 
manipulation and deflection of the instrument tip to expose mucosal surfaces on the proximal 
sides of the haustral folds and flexures.  Because we found that the FUSE colonoscope was also 
inferior with regard to the time for cecal insertion, (possibly because the FUSE insertion tubes 
are “floppier” than Olympus instruments) we conclude that in the hands of careful examiners, 
high-definition forward-viewing colonoscopes have superior performance to the FUSE 
colonoscopes.  It is possible that a wide angle instrument with image resolution comparable 
with Olympus high-definition colonoscopes might provide superior detection. However, to our 
knowledge, no such device exists at the present time, and the FUSE colonoscope is being 
withdrawn from the commercial market after purchase of EndoChoice by Boston Scientific. 
Thus, whether a super wide-angle colonoscope can outperform a 170⁰ angle of view high-
definition instrument is uncertain and must await development of new technology and further 
investigation.   
 
Our data indicate that with regard to adjunctive devices that fit over the tip of an HD forward-
viewing colonoscope, Endocuff is a dominant strategy over EndoRings and no device.  First, 
there was a significant increase of APC with Endocuff compared to control colonoscopy, and 
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ADR was higher with Endocuff compared with EndoRings and control colonoscopy.  A marked 
difference in detection with Endocuff at one center, which contributed the smallest group of 
patients to the overall study, had an important effect on this conclusion, though a numerical 
increase with a trend toward statistical significance was also seen at the largest participating 
site.  There was no disadvantage with Endocuff with regard to insertion. Thus, overall Endocuff 
produced improved detection with no detriment to insertion except for an occasional patient 
with an angulated sigmoid colon in which passage of the colonoscope required removal of the 
cuff.  Further, the finding that Endocuff resulted in gains in detection even in high-level 
detectors, who would be expected to have superior technique with standard instruments, 
suggests that Endocuff could potentially produce detection gains for examiners with any 
baseline level of detection.  Thus, Endocuff may overcome mucosal exposure problems that 
cannot be overcome with an HD forward-viewing colonoscope alone.  
  
In this study, Endocuff allowed an ADR that was at least 7 percentage points higher (95% CI, 3%-
16%) than the other 3 arms of the study.  A recent study found that each 1% gain in ADR 
resulted in a 3% drop in the risk of interval cancer and a 5% drop in the risk of fatal interval 
cancer 
3
.  Whether such impacts on interval cancer will occur in very high-level detectors is 
uncertain, but our results indicate that potentially important gains in ADR are achievable with 
Endocuff even by detectors with very high ADRs using standard instruments.  Endocuff was 
associated with gains in APC of 17% to 40% compared to the other 3 arms.  This difference in 
overall adenoma detection could also result in important protective effects against interval 
cancer, although the relationship of APC to interval cancer protection has not yet been 
described.  Although we did not formally address the cost-effectiveness of Endocuff, the cost of 
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Endocuff is low in the United States compared with the cost of colonoscopy, and would be 
unlikely to adversely affect the cost-effectiveness of improving the quality of adenoma 
detection 
21,22
. 
 
The reasons why EndoRings did not match Endocuff with regard to detection are not clear.  
From a mucosal exposure perspective, the ability of EndoRings to deflect folds seems 
comparable to Endocuff. In the left side of the colon, EndoRings seems to have even more of a 
tendency than Endocuff to straighten the lumen and flatten the haustral folds.  However, the 
mucosal gripping properties of EndoRings seem to cause it to jump back 2 or 3 folds at times 
during withdrawal through the sigmoid, and it can be difficult to reinsert the instrument to the 
point where slippage began.  In any case, our data suggest that EndoRings creates greater 
problems for colonoscope insertion than Endocuff, which certainly relates to its larger diameter 
and bulkier profile.  Taken together, our data suggest that Endocuff is a more effective and 
easier to use device than EndoRings.  
 
Strengths of our study include large size, the use of multiple centers, and the testing of multiple 
devices.  This design allowed a comparison of available devices in a fashion not previously 
available to practicing colonoscopists.  Further, we used the best available versions of each 
technology throughout the study.   We did not see evidence that successive generations of 
FUSE or EndoRings were associated with increasing detection, suggesting that our results apply 
to the latest generations of these devices. Next, we actively forced the inspection times in the 4 
study arms to be equal, because withdrawal time is well known to influence detection (23), and 
failure to control inspection time can disrupt the interpretation of a detection trial 23.   
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Limitations of our study were primarily that the recruitment was uneven across the sites, and 
there were some differences between sites with regard to detection.  These differences suggest 
some operator dependence applies to these devices, such as the very large increase in APC with 
Endocuff relative to other devices in New York.  However many of the trends seen in the overall 
study were consistent across the individual sites, including the detection of adenomas and 
serrated lesions, and insertion times.  Certainly direct comparisons between mucosal exposure 
devices by other investigators could be informative.  However, we acknowledge that the 
operator dependence demonstrated in the study indicates that some caution is appropriate in 
concluding generalizability.   Finally, endoscopists were not blinded to which device was in use.  
This is a consistent problem with colonoscopy detection studies, and these studies depend on 
the investigating endoscopists  approaching the use of each device without bias.   
 
The version of Endocuff that we used is no longer commercially available and has been replaced 
by Endocuff Vision (Arc Medical Design, Leeds, UK).  Endocuff Vision has fingers that are 3 mm 
longer than those on Endocuff, and there is only one ring of fingers.  There are no direct 
comparative studies of Endocuff Vision and Endocuff.  Our anecdotal impression of the fold 
flattening achieved with Endocuff Vision is that it is as or more effective than Endocuff, with no 
reduction of insertability.  We upgraded the EndoRings and FUSE colonoscopes as upgrades 
became available during the study.  Although the use of upgraded devices makes study 
interpretation more challenging, we considered that failure to upgrade and using only older 
devices would also subject the study to criticism.  Again, we saw no significant improvement in 
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ADRs over the course of the study within the EndoRings or FUSE arms, suggesting that our 
conclusions regarding detection remain valid with the latest generations of these devices.   
 
To the extent that our results endorse the routine use of Endocuff in clinical practice, 
practitioners might be interested in our impressions of how the device affects actual 
colonoscopy performance. Our collective impression is that the use of Endocuff in routine 
colonoscopic examination is easy for experienced endoscopists to learn, and does not adversely 
affect the performance of routine polypectomies.   We suspect it may have the potential to 
make the process of examining the proximal sides of folds faster, as has been suggested in 
retrospective uncontrolled evaluations 
24
, but which has not been tested as a primary endpoint 
of randomized trials.  We did not routinely or systematically attempt terminal intubation during 
the study, but our impression was that Endocuff does reduce the ease of and success rate of  
terminal ileal intubation, consistent with the results of other studies  
25
.  Finally, attention to 
difficult sigmoid colons is needed in considering use of Endocuff. In the current study, about 
1.5% of subjects had sigmoid colons that did not allow passage of Endocuff, and at Indianapolis 
about 2% of screened subjects were excluded before randomization because of known 
diverticular disease that might have made sigmoid passage with Endocuff or EndoRings difficult 
or impossible.  We note that the detection gains found in this study with Endocuff were largely 
in diminutive lesions (Supplementary Table 1), and the clinical significance of detection gains in 
diminutive lesions remains uncertain.  Improved detection of diminutive lesions may be 
generally associated with improved detections of large lesions, but that suggestion is not 
proven true by these data.  Further, we did not perform a formal cost analysis of Endocuff use, 
and have not evaluated the cost-effectiveness of using Endocuff routinely in colonoscopy. 
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In conclusion, in a prospective randomized controlled trial we demonstrated that detection 
with high-definition forward-viewing colonoscopes is superior to a very wide angle colonoscope 
system, which in all in its iterations had what seemed to be recognizably inferior image 
resolution.  Thus, in the hands of high-level detectors, image resolution trumps angle of view 
for adenoma detection during colonoscopy.  Next, we showed that use of an adjunct (Endocuff) 
on the end of a HD forward-viewing colonoscope produced gains in adenoma detection even in 
the hands of examiners who are very skilled with standard instruments lacking adjunctive 
devices.  Further, Endocuff produced no reduction of insertion capability that was clinically 
important.  Finally, our results indicate that the design of Endocuff is superior to the design of 
EndoRings as a mucosal exposure device for colonoscopy.   
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Table 1. Inclusion and exclusion criteria 
Inclusion criteria: 
• Screening, surveillance or diagnostic colonoscopy 
• and ≥ 50 years of age 
Exclusion criteria: 
• Any large-bowel resection 
• inflammatory bowel disease  
• Any polyposis syndrome 
• Any family history of polyposis syndromes 
• Referral for a previous incomplete colonoscopy 
• Referral for removal of a polyp  
• Referral for positive fecal blood test 
• Anticipated severe sigmoid angulation 
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Table 2.  Demographics and procedure indications 
  Study arm 
Control* Endocuff** EndoRings*** FUSE 
Number of 
subjects n = 295 n = 299 n = 295  n = 299 
Age(years) 62.6 (8.3) 63.2 (8.2) 62.3 (7.9) 62.3 (8.7) 
Female 139 (47%) 141 (47%) 156 (53%) 146 (49%) 
Race         
White 272 (92%) 276 (92%) 276 (94%) 269 (90%) 
Black 13 (4%) 15 (5%) 13 (4%) 20 (7%) 
Hispanic 5 (2%) 6 (2%) 5 (2%) 4 (1%) 
Asian 4 (1%) 2 (1%) 1 (<1%) 5 (2%) 
Other 1 (<1%) 0 (0%) 0 (0%) 0 (0%) 
Indication         
Screening 127 (43%) 126 (42%) 123 (42%) 128 (43%) 
Surveillance 151 (51%) 150 (50%) 152 (52%) 154 (52%) 
Diagnostic 16 (5%) 23 (8%) 20 (7%) 16 (5%) 
 
*Control: high-definition forward-viewing Olympus 190 or H180 colonoscope 
**Control instrument with Endocuff 
***Control instrument with EndoRings 
FUSE: Full Spectrum Endoscopy 
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Table 3. Detection endpoints in the intent- to - treat analysis 
  
Study arm 
Control Endocuff EndoRings FUSE 
Number of subjects n = 295 n = 299 n = 295  n = 299 
Adenomas per 
colonoscopy 
        
All sites
+
 1.53 (2.33)* 1.82 (2.58) 1.55 (2.42) 1.30 (1.96) 
Indianapolis 1.89 (2.69) 2.17 (2.88) 1.97 (2.77) 1.59 (2.18) 
Milan 0.83 (1.18) 0.80 (1.25) 0.72 (1.17) 0.68 (1.19) 
New York++ 0.92 (1.15) 2.00 (2.34) 0.75 (0.94) 0.80 (1.32) 
Adenoma detection rate         
All sites
+++
 166 (56%)** 191 (64%) 167 (57%) 154 (52%) 
Indianapolis 117 (61%) 137 (70%) 127 (65%) 115 (58%) 
Milan 37 (47%) 35 (47%) 29 (39%) 28 (37%) 
New York 12 (48%) 19 (68%) 11 (46%) 11 (44%) 
SSP per colonoscopy         
All sites++++ 0.17 (0.54)* 0.17 (0.54) 0.20 (0.81) 0.18 (0.74) 
Indianapolis 0.24 (0.64) 0.23 (0.63) 0.29 (0.98) 0.25 (0.89) 
Milan 0.03 (0.16) 0.04 (0.26) 0.01 (0.12) 0.03 (0.16) 
New York 0.04 (0.20) 0.07 (0.26) 0.04 (0.20) 0.04 (0.20) 
SSP detection rate         
All sites
+++++
 36 (12%)** 33 (11%) 33 (11%) 30 (10%) 
Indianapolis 33 (17%) 29 (15%) 31 (16%) 27 (14%) 
Milan 2 (3%) 2 (3%) 1 (1%) 2 (3%) 
New York 1 (4%) 2 (7%) 1 (4%) 1 (4%) 
Polyp detection rate         
All sites
++++++
 226 (77%)** 247 (83%) 231 (78%) 212 (71%) 
Indianapolis 
@
 162 (84%) 175 (89%) 171 (87%) 155 (78%) 
Milan 46 (59%) 50 (68%) 42 (56%) 38 (51%) 
New York 18 (72%) 22 (79%) 18 (75%) 19 (76%) 
 
* Designated polyp type per colonoscopy (SD) 
** Number of patients with designated polyp type (%) 
+ Control, Endocuff, EndoRings higher than FUSE (all p < 0.001) 
+ Endocuff > control (p = 0.014) 
++ Endocuff > EndoRings (p = 0.008), FUSE (p = 0.011) and control (p = 0.027) in New York; no difference in study 
arms for APC at Indianapolis (p = 0.137 or Milan (p = 0.848) 
+++ Endocuff (p < 0.001), EndoRings (p = 0.001), control (p = 0.006) all higher than FUSE.  Endocuff higher than 
EndoRings (p < 0.001) and control (p = 0.003).  No differences in ADR by site 
++++ EndoRings higher than FUSE (p < 0.001) and control (p < 0.001) FUSE higher than control (p < 0.001)  
+++++ Endocuff (p = 0.009), control (p < 0.001) higher than FUSE.  Control higher than Endocuff (p=0.047) and 
EndoRings (p = 0.004) 
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++++++ Endocuff (p < 0.001), EndoRings (p = 0.002), control (p < 0.001) higher than FUSE. Endocuff higher than 
EndoRings (p = 0.008) and control (p < 0.001) 
@At Indianapolis Endocuff (p = 0.004) and EndoRings (p = 0.015) higher than FUSE. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 1. Numbers of histologically proven conventional adenomas and sessile serrated polyps by 
size and location (right colon = cecum, ascending, and hepatic flexure) in the 4 study arms 
 
Conventional adenomas 
  Study Arm 
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Number of 
subjects  n = 295 n = 299 n = 295 n = 299 
Location Size Control Endocuff EndoRings FUSE 
All All 445 543 463 385 
 1-5mm 336 (76) 424 (78) 342 (74) 299 (78) 
 6-9mm 73 (16) 83 (15) 79 (17) 63 (16) 
 >=10mm 36 (8) 36 (7) 42 (9) 23 (6) 
Distal to 
the hepatic 
flexure All 240 290 250 191 
 1-5mm 176 (73) 225 (76) 180 (72) 154 (81) 
 6-9mm 45 (19) 46 (16) 48 (19) 28 (15) 
 >=10mm 19 (8) 19 (7) 22 (9) 9 (5) 
Right Colon All 205 253 213 194 
 1-5mm 160 (78) 199 (79) 162 (76) 145 (75) 
 6-9mm 28 (14) 37 (15) 31 (15) 35 (18) 
 >=10mm 17 (7) 17 (7) 20 (9) 14 (7) 
 
Sessile serrated polyps 
  Study Arm 
Number of 
subjects  n = 295 n = 299 n = 295  n = 299 
Location Size Control Endocuff EndoRings FUSE 
All All 51 50 57 53 
 1-5mm 28 (55) 20 (40) 21 (37) 21 (43) 
 6-9mm 14 (27) 13 (26) 16 (28) 13 (32) 
 >=10mm 9 (18) 17 (34) 20 (35) 19 (36) 
Distal to 
the hepatic 
flexure All 31 18 28 28 
 1-5mm 19 (49) 9 (50) 13 (46) 12 (43) 
 6-9mm 8 (26) 3 (17) 8 (29) 9 (32) 
 >=10mm 4 (13) 6 (33) 7 (25) 7 (25) 
Right Colon All 20 32 29 25 
 1-5mm 9 (45) 11 (34) 8 (28) 9 (36) 
 6-9mm 6 (30) 10 (31) 8 (28) 4 (16) 
 >=10mm 5 (25) 11 (34) 13 (45) 12 (48) 
 
*number of polyps (% of all polyps in this location that are in this size group) 
 
 
Table 4. Procedure times 
 
 
  
Study arm 
Control Endocuff EndoRings FUSE 
Cecal insertion time 
seconds(SD) 
 n = 295 n = 299  n= 295  n = 299  
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All sites
+
 422 (319) 354 (216) 403 (263) 468 (311) 
Indianapolis 366 (243) 320 (179) 352 (191) 395 (225) 
Milan 642 (405) 503 (254) 581 (356) 731 (385) 
New York 170 (62) 193 (93) 251 (110) 242 (80) 
Cecal insertion time 
when no fellow 
involved-seconds (SD) 
n =  173 n =  169 n =  172 n =  176 
All sites
++
 320 (256) 265 (173) 331 (222) 380 (252) 
Indianapolis 283 (185) 239 (127) 277 (127) 340 (169) 
Milan 556 (378) 438 (269) 588 (345) 718 (401) 
Inspection time 
seconds(SD) 
n = 295  n = 299 n = 295  n = 299 
All sites
+++ 
444 (103) 419 (95) 417 (147) 421 (112) 
Indianapolis 418 (91) 392 (89) 388 (160) 378 (83) 
Milan 501 (109) 492 (78) 484 (92) 522 (120) 
New York 467 (95) 414 (84) 438 (96) 454 (81) 
 
n = number of insertions in designated group performed with no participation by a fellow  
+
FUSE longer than Endocuff (p = 0.006) and control (p = 0.016), EndoRings longer than Endocuff (p = 0.020) (site 
difference similar but not shown) 
++When no fellow involved in insertion FUSE longer than Endocuff (p < 0.001), EndoRings (p = 0.017) and control 
(p = 0.001) EndoRings longer than Endocuff (p= 0.014) 
By site: FUSE longer than Endocuff and control at all sites; EndoRings longer than Endocuff and control in New 
York, FUSE longer than EndoRings in Milan, control longer than Endocuff in Milan. 
+++No significant difference overall. By site, control significantly shorter than Endocuff, EndoRings, and FUSE in 
Indianapolis. 
 
 
 
 
 
 
 
 
 
Supplementary Table 2: Detection endpoints in the per protocol analysis 
 
  
Study arm 
Control Endocuff Endorings FUSE 
Number of subjects n = 295 n = 299 n = 295 n = 299 
Adenomas per 
colonoscopy 
        
All sites
+
 1.53 (2.33)* 1.84 (2.59) 1.57 (2.43) 1.30 (1.96) 
Indianapolis 1.89 (2.69) 2.21 (2.88) 1.98 (2.78) 1.59 (2.18) 
Milan 0.83 (1.18) 0.80 (1.25) 0.72 (1.18) 0.68 (1.19) 
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New York
++
 0.92 (1.15) 2.07 (2.35) 0.82 (0.96) 0.83 (1.34) 
Adenoma detection rate         
All sites
+++
 166 (56%)** 191 (65%) 165 (57%) 154 (52%) 
Indianapolis 117 (61%) 137 (71%) 126 (65%) 115 (58%) 
Milan 37 (47%) 35 (47%) 28 (38%) 28 (37%) 
New York 12 (48%) 19 (70%) 11 (50%) 11 (46%) 
SSP per colonoscopy         
All sites++++ 0.17 (0.54)* 0.17 (0.54) 0.20 (0.82) 0.18 (0.54) 
Indianapolis 0.24 (0.64) 0.23 (0.63) 0.30 (0.98) 0.25 (0.89) 
Milan 0.03 (0.16) 0.04 (0.26) 0.01 (0.12) 0.03 (0.16) 
New York 0.04 (0.20) 0.07 (0.27) 0.05 (0.21) 0.04 (0.20) 
SSP detection rate         
All sites
+++++
 36 (12%)** 33 (11%) 33 (11%) 30 (10%) 
Indianapolis 33 (17%) 29 (15%) 31 (16%) 27 (14%) 
Milan 2 (3%) 2 (3%) 1 (1%) 2 (3%) 
New York 1 (4%) 2 (7%) 1 (5%) 1 (4%) 
Polyp detection rate         
All sites
++++++
 22 (77%)* 247 (84%) 229 (79%) 213 (71%) 
Indianapolis 
@
 163 (85%) 174 (90%) 171 (89%) 156 (78%) 
Milan 46 (59%) 50 (68%) 41 (55%) 38 (51%) 
New York 19 (76%) 23 (85%) 17 (77%) 19 (79%) 
 
* Designated polyp type per colonoscopy (SD) 
** Number of patients with designated polyp type (%) 
+ Standard, Endocuff, Endorings higher than FUSE (all p < 0.001) 
+ Endocuff > Endorings (p = 0.048) and standard (p = 0.004) 
++ Endocuff > Endorings (p = 0.011), FUSE (p = 0.010) and standard (p = 0.018) in New York; no difference in 
study arms for APC atIndianapolis (p = 0.16) or Milan (p = 0.845) 
+++ Endocuff (p < 0.001), Endorings (p = 0.004), standard (p = 0.007) all higher than FUSE.  Endocuff higher than 
Endorings (p < 0.001) and standard (p = 0.004).  No differences in ADR by site 
++++ Endorings higher than FUSE (p < 0.001) and standard  (p < 0.001) FUSE higher than standard (p < 0.001)  
+++++ Endocuff (p = 0.002), Endorings (p = 0.041), standard (p < 0.001) higher than FUSE.  Standard higher than 
Endorings (p = 0.015) 
++++++ Endocuff (p < 0.001), Endorings (p = 0.009), standard (p < 0.001) higher than FUSE. Endocuff higher than 
Endorings (p = 0.16) and standard (p < 0.001) 
@At Indianapolis Endocuff (p = 0.003) and Endorings (p = 0.007) higher than FUSE. 
 
 
 
Figure Legends 
 
Figure 1: Flow of patients through the study. 
 
Figure 2: The Endocuff (left) and the revised EndoRings (right) devices used in the study. 
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Acronyms 
FUSE: Full-Spectrum Endoscopy 
HD: high definition 
APC: adenomas per colonoscopy 
ADR: adenoma detection rate 
DR: Douglas Rex 
AR: Alessandro Repici 
SG: Seth Gross 
U.S.A: United States of America 
MN: Minnosta 
APC: adenomas per colonoscopy 
SSPC: sessile serrated polyps per colonoscopy 
SPDR: sessile serrated detection rate 
GEE: generalized estimating equation 
BBPS: Boston Bowel Preparation Score 
NC: North Carolina 
PDR: polyp detection rate 
SSP: sessile serrated polyps 
FIT: fecal immunochemical test 
US: United States 
SD: standard deviation 
 
 
